# A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

> **NCT03486353** · PHASE2 · WITHDRAWN · sponsor: **Fujifilm Pharmaceuticals U.S.A., Inc.**

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** FF-10501-01
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03486353
- **Lead sponsor:** Fujifilm Pharmaceuticals U.S.A., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-01
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Program terminated
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486353, "A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03486353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*